Tags

Type your tag names separated by a space and hit enter

Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1.
Am J Ophthalmol. 2005 Aug; 140(2):325-7.AJ

Abstract

PURPOSE

To report canalicular stenosis as a side effect of the new antineoplastic agent S-1.

DESIGN

Interventional case series.

METHODS

Three patients who received S-1 for treatment of gastrointestinal cancer at a tertiary cancer center were evaluated and treated for epiphora.

RESULTS

Two patients were found to have severe canalicular stenosis and nasolacrimal duct blockage after approximately 6 months of S-1 therapy. One patient underwent dacryocystorhinostomy with silicone tube placement on one side and dacryocystorhinostomy and Pyrex glass tube placement on the other side. The other patient declined a surgical intervention. One additional patient with epiphora had punctal stenosis early in the course of S-1 therapy. His epiphora resolved after probing and irrigation and 4 weeks of topical corticosteroid therapy.

CONCLUSIONS

Canalicular and nasolacrimal duct blockage is a previously unreported side effect of S-1 and should be recognized and treated at its earliest possible stage so that complete closure of the canaliculi can be avoided.

Authors+Show Affiliations

Section of Ophthalmology, Department of Plastic Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. besmaeli@mdanderson.orgNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

16086962

Citation

Esmaeli, Bita, et al. "Canalicular and Nasolacrimal Duct Blockage: an Ocular Side Effect Associated With the Antineoplastic Drug S-1." American Journal of Ophthalmology, vol. 140, no. 2, 2005, pp. 325-7.
Esmaeli B, Golio D, Lubecki L, et al. Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1. Am J Ophthalmol. 2005;140(2):325-7.
Esmaeli, B., Golio, D., Lubecki, L., & Ajani, J. (2005). Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1. American Journal of Ophthalmology, 140(2), 325-7.
Esmaeli B, et al. Canalicular and Nasolacrimal Duct Blockage: an Ocular Side Effect Associated With the Antineoplastic Drug S-1. Am J Ophthalmol. 2005;140(2):325-7. PubMed PMID: 16086962.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1. AU - Esmaeli,Bita, AU - Golio,Dominick, AU - Lubecki,Linda, AU - Ajani,Jaffer, PY - 2004/12/10/received PY - 2005/01/26/revised PY - 2005/01/29/accepted PY - 2005/8/10/pubmed PY - 2005/9/1/medline PY - 2005/8/10/entrez SP - 325 EP - 7 JF - American journal of ophthalmology JO - Am J Ophthalmol VL - 140 IS - 2 N2 - PURPOSE: To report canalicular stenosis as a side effect of the new antineoplastic agent S-1. DESIGN: Interventional case series. METHODS: Three patients who received S-1 for treatment of gastrointestinal cancer at a tertiary cancer center were evaluated and treated for epiphora. RESULTS: Two patients were found to have severe canalicular stenosis and nasolacrimal duct blockage after approximately 6 months of S-1 therapy. One patient underwent dacryocystorhinostomy with silicone tube placement on one side and dacryocystorhinostomy and Pyrex glass tube placement on the other side. The other patient declined a surgical intervention. One additional patient with epiphora had punctal stenosis early in the course of S-1 therapy. His epiphora resolved after probing and irrigation and 4 weeks of topical corticosteroid therapy. CONCLUSIONS: Canalicular and nasolacrimal duct blockage is a previously unreported side effect of S-1 and should be recognized and treated at its earliest possible stage so that complete closure of the canaliculi can be avoided. SN - 0002-9394 UR - https://www.unboundmedicine.com/medline/citation/16086962/Canalicular_and_nasolacrimal_duct_blockage:_an_ocular_side_effect_associated_with_the_antineoplastic_drug_S_1_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9394(05)00152-2 DB - PRIME DP - Unbound Medicine ER -